Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer.

Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates targeting chronic hepatitis B, HPV-related disease, coeliac disease and prostate cancer.

The company co-invented the viral vector technology underlying a widely deployed COVID-19 vaccine.